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Expression of Epstein-Barr virus (EBV) DNA and cloned DNA
fragments in human lymphocytes following Sendai virus
envelope-mediated gene transfer*
(Epstein-Barr virus/lymphocyte transformation/gene transfer)

DAVID J. VOLSKYt, THOMAS GROSSt, FARUK SINANGILt, CHARLES KUSZYNSKIt, RONALD BARTZATTt,
TIMOTHY DAMBAUGHt, AND ELLIOTT KIEFFf
tDepartment of Pathology and Laboratory Medicine, University of Nebraska Medical Center, 42nd & Dewey Avenue, Omaha, NB 68105; and tKovler
Virology Laboratory, University of Chicago, 910 East 58th Street, Chicago, IL 60637

Communicated by Werner Henle, June 4, 1984

ABSTRACT
Purified EBV DNA and cloned DNA fragments were trapped in Sendai virus (SV) envelopes during envelope reconstitution. The DNA-loaded reconstituted envelopes (RSVE/DNA) served as gene-transfer vehicles using the
capability of RSVE to fuse with normal and tumor cells. The
efficiency of RSVE-mediated EBV DNA transfer into lymphoid tumor cells and fresh human lymphocytes was 5-10% of
the enveloped 3H-labeled EcoRI fragment B of EBV DNA. Purified intracellular EBV (B95-8 strain) DNA induced EBV nuclear antigen (EBNA) in 0.2-1 % of human lymphocytes, transiently stimulated cellular DNA synthesis, but did not fully
transform cells. Cloned Sal I F1 fragment [-9 kilobase pairs
(kbp)] and a smaller BamHI K (5.2 kbp) fragment from the
same region of B95-8 EBV DNA induced EBNA in 2-4% of
human lymphocytes but did not stimulate DNA synthesis nor
transform cells. Cloned BamHI D1 fragment (z9 kbp) from
AG-876 virus DNA, or a combination of cloned BamHI X and
H fragments (-2 and 7 kbp, respectively) from the similar
region of B95-8 virus DNA, significantly stimulated lymphocyte DNA synthesis, but EBNA could not be detected and
transformation was not achieved. Early antigen and viral capsid antigen were not observed with any of the fragments tested.
Our results suggest that the induction of EBNA and stimulation of lymphocyte proliferation are not controlled by the same
region of EBV DNA.

injection experiments employing recombinant EBV DNA
have been performed with already transformed or permanently growing cells (4, 10-12). Introduction of EBV DNA
into normal human T lymphocytes (7), human placental cells
(6), or rodent splenocytes (5) resulted in virus replication
rather than in vitro transformation. Possibly, the cell-transforming activity of EBV is limited to natural host cells of the
virus-i.e., the mature human B lymphocytes and epithelial
cells (1, 3, 5).
The purpose of these experiments is to begin to assay the
function of parts of the EBV genome in normal B cells. Since
DNA transfer into lymphocytes by calcium phosphate,
DEAE-dextran, and protoplast fusion are inefficient processes, we have tried a different approach-i.e., use of
DNA-loaded reconstituted Sendai virus (SV) envelopes as
gene-transfer vehicles (13-15). SV envelopes (SVE) can be
isolated, solubilized, and reconstituted (RSVE), retaining
the ability to fuse with target cell membranes (16). EBV nucleocapsids can be enveloped by RSVE (14). The fusible
RSVE/EBV vesicles have been used to transfer EBV
genome into an extended host range (14). The internalized
viral DNA was expressed in up to 1% of the target cells (14).
These experiments suggested the possibility that EBV DNA
present during reconstitution could be enveloped and transferred into living eukaryotic cells.
In the present work, we present data on the application of
the RSVE system for transferring purified EBV DNA and
cloned DNA fragments into fresh human lymphocytes. The
biological activity of EBV DNA and DNA fragments in human B cells was monitored by following stimulation of cellular DNA synthesis, cell immortalization, and expression of
EBV-determined antigens. Our results suggest that cell
transformation by EBV may require collaboration between
several viral and cellular genes.

Epstein-Barr virus (EBV) is a lymphotropic transforming
herpesvirus that causes infectious mononucleosis and is associated with Burkitt lymphoma, nasopharyngeal carcinoma, and several acute lymphoproliferative diseases (reviewed in refs. 1-3). Classical genetic mapping of viral functions is hampered by the host range restriction to B
lymphocytes and restricted permissivity of B cells for virus
replication (1, 3). Attempts to extend the host range of the
virus by DNA transfection, microinjection, or virus-receptor
transplantation resulted in virus replication (refs. 4-6; reviewed in ref. 7). Many viral proteins have been mapped to
fragments of EBV DNA by using cloned fragments of EBV
DNA and hybrid selection, in vitro translation, and immunoprecipitation (8, 9). Some viral proteins, including EBV nuclear antigen (EBNA), have been mapped by using cloned
EBV DNA fragments in prokaryotic or eukaryotic expression systems (10, 11).
Although a great deal is known about viral gene expression in latently infected growth-transformed cells, the celltransforming functions of EBV have not been distinguished
from viral genes whose function may be solely related to
maintenance of viral latency. Some transfection and micro-

MATERIALS AND METHODS
Cells. Human cord blood lymphocytes or cells from EBVseronegative donors were separated on Ficoll-Isopaque
(Pharmacia). B cell-enriched fractions were obtained by separating human B and T cells on nylon wool columns. Tumor
cells utilized in this study were Raji (EBV-positive BL; ref.
17), Ramos (EBV-negative American BL; ref. 18), and B95-8
(EBV-transformed marmoset lymphocytes; ref. 19). All cells
Abbreviations: EBV, Epstein-Barr virus; EBNA, EBV nuclear
antigen; EA, early antigen; VCA, viral capsid antigen; SV, Sendai
virus; SVE, SV envelopes; RSVE, reconstituted SVE; RSVE/
DNA, DNA-loaded RSVE; ACIF, anti-complement immunofluorescence.

*Preliminary results of this study have been reported during the University of California, Los Angeles, Symposium on Normal and
Neoplastic Hematopoiesis, March 27-April 1, 1983, Steamboat
Springs, CO (13).

The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
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FIG. 1. Restriction endonuclease map of prototypic EBV isolate (22), indicating the position of the cloned EBV (AG-876) BamHI D1
fragment and EBV (B95-8) Sal I F1 fragment below the linkage map of BamHI and EcoRI fragments for a typical EBV isolate. The middle line
indicates the location of direct terminal repeat sequences, TR, and discrete direct internal repeat sequences, IR1-4, separated by unique
sequence regions, U1-5 (24). Also shown is the region of DNA deleted from the nontransforming EBV (P3HR-1) isolate (23, 25).

were maintained as stationary suspension cultures in RPMI
1640 (GIBCO) medium supplemented with 10o fetal bovine
serum, penicillin (100 ,ug/ml), and streptomycin (100 pg/ml).
Viruses. SV was propagated and its hemagglutinating titer
was determined as described (5, 16). One milligram of SV
was approximately equivalent to 15,000 hemagglutination
units. The transforming B95-8 virus was harvested from supernatants of starving B95-8 cells as described (5) and concentrated to 0.2% of initial volume. The virus was capable of
inducing EBNA in 10% of Ramos cells 2 days after infection
at a 1:200 dilution and was used at a 1:100 dilution.
EBV DNA and Cloned DNA Fragments. The procedure for
isolation of high molecular weight intracellular EBV DNA
by repetitive CsCl equilibrium centrifugation has been described (20). The cloned BamHI X, H, and K fragments and
Sal I F fragment from B95-8 EBV DNA and the cloned
EcoRI fragments from W91 EBV DNA were isolated, propagated, and characterized as described (21, 22). The cloned
BamHI D1 fragment from AG-876 EBV DNA occupies the
same map location as the B95-8 EBV BamHI X and H DNA
fragments (refs. 17 and 23; see also the restriction endonuclease map in Fig. 1).
Preparation of DNA-Loaded SV Vesicles (RSVE/DNA).
The four principal steps of the procedure and its efficiency
are summarized in Table 1. SV particles (5 mg of viral protein) in 100 mM NaCl/50 mM Tris HCl, pH 7.4, were extracted by Triton X-100 for 1 hr at room temperature. The
detergent/SV protein ratio was 2:1 (wt/wt). After centrifugation at 100,000 x g for 1 hr, the supernatant containing -1
mg of SVE protein in the detergent was collected. Tritonsolubilized SVE (1 mg) and EBV DNA (50 ug) or cloned
EBV DNA fragments (50 Hg) were mixed (step 1 in Table 1)
and dialyzed in Spectrapor 2 dialysis bags at 4°C for 48 hr
against 2 mM CaCl2/2 mM MgCl2/10 mM Tris-HCl, pH
7.4/2 mM NaN3/0.1 mM phenylmethylsulfonyl fluoride
(steps 1 and 2 in Table 1). The RSVE/+DNA step 2 vesicles
were then digested with a DNase (Sigma; 50 ,g/ml) for 1 hr
Table 1. Procedure of EBV DNA entrapment in RSVE
and its efficiency
% of
starting
Amount
material
Radioactivity, of DNA,
radioactivity
,ug
cpm x 10-6
Step
100
1.1
50
(1) SVE + EcoRI [3H]B
64
32
0.7
(2) RSVE/+ EcoRI [3H]B
2.5
5.0
0.055
(3) RSVE/EcoRI [3H]B
Triton X-100-extracted SVE are mixed with EBV DNA and a
probe (EcoRI [3H]B) (step 1). Removal of the detergent by dialysis
results in envelope reconstitution (RSVE). Some of the DNA probe
is trapped inside the vesicles, but most is adsorbed on the surface
(RSVE/+ EcoRI [3H]B) (step 2). DNase treatment of the RSVE/+
EcoRI [3H]B vesicles and ultracentrifugation remove the adsorbed
DNA (RSVE/EcoRI [3H]B) (step 3). For further details, see Materials and Methods.

at 37°C to remove any DNA not entrapped inside the vesicles. The vesicles then were sedimented at 100,000 x g for 1
hr at 4°C to remove nonreconstituted elements and DNase
and were resuspended in 0.25 ml (step 3, final preparation of
RSVE/DNA vesicles, in Table 1).
RSVE-Mediated DNA Transfer. RSVE/EBV DNA vesicles were absorbed at 4°C to target cells suspended in a fusion buffer (160 mM NaCl/20 mM Tricine-NaOH, pH 7.5).
After 10 min at 4°C, 5 mM CaCl2 was added, followed by a
20- to 30-min incubation at 37°C. The cells were then washed
twice in RPMI 1640 medium, resuspended at 2 x 106 cells
per ml, and cultivated under standard conditions.
Cellular DNA Synthesis-Stimulation Assay. Cellular DNA
synthesis was followed by measuring incorporation of
[3H]thymidine (2.0 Ci/mmol, New England Nuclear; 1 Ci =
37 GBq). Triplicate cultures of cells (2 x 105 cells per 0.1 ml
per well) were kept in Falcon 96-well microtiter plates. At
different times (7, 14, and 21 days) after EBV DNA transfer
or EBV infection, 0.8 ,Ci of [ H]thymidine was added to
each well and incubated at 37°C for 16-20 hr. The cells were
collected on glass fiber filters by a Titertek cell harvester
and counted by liquid scintillation using Insta-Gel (Packard).
Immunofluorescence Staining. EBNA was determined by
anti-complement immunofluorescence (ACIF) assay (26) using smears of 2:1 (vol/vol) acetone/methanol-fixed cells 2 or
7 days after the DNA transfer or EBV infection. EBV-positive and EBV-negative sera were used at 1:10 dilution. Early
antigen (EA) and viral capsid antigen (VCA) were determined by indirect immunofluorescence (27) using mouse
monoclonal anti-EA (D and R) and anti-VCA antibodies
(Biotech, Rockville, MD) and fluorescein isothiocyanateconjugated goat anti-mouse immunoglobulin (Cappel Laboratories, Cochranville, PA) as a second antibody.

RESULTS
Trapping of EBV DNA in RSVE and Transfer into Lymphocytes. The efficiency of EBV DNA entrapment in RSVE was
determined by using 3H-labeled nick-translated EcoRI fragment B probe (EcoRI [3H]B) (Table 1). Although more than
50% of the DNA was associated with the reconstituted vesicles (step 2), only 5% of it was trapped inside the vesicles, as
judged by the resistance to DNase digestion (step 3). Titration experiments with various amounts of DNA added to the
co-reconstitution mixture revealed that maximal entrapment
could be achieved with 40-50 ,ug of EBV DNA per 1 ml of
solubilized SVE proteins (unpublished data). Up to 2.5 ug of
DNA could be loaded into the reconstituted vesicles (2 mg of
envelope protein) under these conditions.
Previously, we have demonstrated that RSVE retained the
cell-binding and -fusing activities of intact virions (5, 14, 16).
As expected, loading with DNA did not impair the cell-recognition properties of the RSVE (Fig. 2). A typical titration
experiment of RSVE/[3H]DNA vesicles against target cells,
in this case Raji, is shown in Fig. 2. The optimal amount of
RSVE that could be added without causing a significant cell

pow~

Biochemistry: Volsky et aL

5928

sow
'4
0

io'
'0

D

4400

2
r.

0~~~~~~~~~

0
u

0

~ ~

m

Proc. Natl. Acad ScL USA 81 (1984)

5
0

~~~~~0
la
0

-o

CO
0

TIC
.0

-0
10
3
0

,

/

A:

'0
-o

,

=
.

2

4

6
I

*

10

24

at 37'C, hr
~~~~~~~Time

/

U

~

20

40

30

Raji cells x 10-6

per

50

ml

FIG. 2. Binding of RSVE/EcoRI [3H]B vesicles to Raji cells at
40C and 370C (Inset). RSVE/EcoRI [3H]B vesicles (25 "I; 5500 cpm)
were adsorbed to Raji cells for 10 min at 40C. The cells were then
washed and analyzed for residual radioactivity. (Inset) RSVE/
EcoRI [3H]B vesicles (125 W1; 27,000 cpm) were adsorbed to 150 x
106 Raji cells and incubated as described above. After taking the 40C
sample, the cells were supplemented with CaCl2 (5 mM), transferred
to 370C for 30 min, washed twice in RPMI containing 10% fetal calf
serum, and cultured under standard conditions at 0.5 x 106 cells per
ml. Samples were taken at the times indicated in the figure and analyzed for the residual radioactivity. The 24-hr sample was first treated with 0.125% trypsin (10 min at 200C) to remove any vesicles that
could still be adsorbed on the cell surface.

lysis was 2-5 ug of envelope protein per 1 x 106 cells.
RSVE-mediated DNA transfer was performed by interacting RSVE/DNA vesicles with target cells at 370C. The main
steps were: (i) adsorption of the vesicles to cells at 40C, (ii)
vesicle-cell fusion at 370C (20-30 min), and (iii) cell culture
and analysis. Fig. 2 Inset shows a quantitative analysis of the
RSVE-mediated gene transfer into Raji cells, with RSVE
containing EcoRI [3H]B probes. About 50% of the added
DNA remained associated with cells at 40C. A subsequent
incubation at 370C for 30 min resulted in decrease of the label, likely because of detachment of unfused DNA-loaded

7

14

21

Time after DNA transfer or infection, days
FIG. 3. Kinetics of cellular DNA synthesis in fresh human lymphocytes after the RSVE-mediated EBV DNA and DNA fragment
transfer or after infection with intact virus. Fresh lymphocytes from
the EBV-seronegative donor were isolated, resuspended in fusion
buffer, and fused with RSVE/DNA as described. After fusion, the
cells were washed in RPMI containing 10%o fetal calf serum and cultured under standard conditions. Cellular DNA synthesis was assayed at indicated time intervals as described. Stimulation is expressed as percentage of mean cpm (incorporated [3H]thymidine)

for each system above the cpm of the control-i.e., cells treated
with empty RSVE. e, Intact B95-8 EBV added to untreated cells; o,
cells exposed to RSVE/DNA; A, cells exposed to RSVE/BamHI
D1 fragment; A, cells exposed to RSVE/Sal I F1 fragment.

vesicles by viral neuraminidase (16). To reveal the actual
interior, cells
were cultured for 24 hr after the fusion, washed, treated with
trypsin (0.125%) to remove any nonfused vesicles, and analyzed for residual radioactivity. About 10% of the added
probe remained associated with the Raji cells, indicating that
the amount of internalized EBV DNA was about 100 molecules per cell (24-hr point in Fig. 2 Inset). The pattern of
RSVE/EcoRI [3H]B vesicle interaction with human B lymamount of EBV DNA transferred into the cell

Table 2. Induction of cell DNA synthesis and EBNA in human lymphocytes after RSVE-mediated DNA transfer
Stimulation of cellular DNA synthesis,
Cell
% EBNASI weeks after infection
positive
transforSystem
1
2
3
cells
mation
RSVE
1
1
1
0
RSVE/EBV DNA
3.1; 1.6; 6.4
2.7; 5.4; 2
1.5; 1
1; 0.2
RSVE/Sal I F1
0.6; 1.3; 0.5
0.97; 0.74
0.3; 2
4; 2; 0.2
RSVE/BamHI K
1
0.9; 0.2
0.5
0.5
RSVE/BamHI D1
3.1; 2.1; 1.5
1.5; 1.7; 2.2
0.9
0; 0
RSVE/BamHI H-X
2.3; 1.8
1
0; 0
RSVE/BamHI D1/Sal I F1
1.1
1.3
NT
RSVE/pBR322
1.1
0.9
0
EBV
2; 8
7.7; 38
30; 40
2; 5
+
Separation of human lymphocytes, reconstitution of EBV DNA or cloned restriction endonuclease fragments with SVE,
and gene transfer were as described. After the transfer, the cells were resuspended in RPMI 1640 with 10% fetal calf serum
and cultured under standard conditions at 2 x 106 cells per ml. EBNA was determined by ACIF assay (26) 2 days after
infection. EA and VCA were determined by direct immunofluorescence. Cellular DNA synthesis was determined by
measuring incorporation of [3H]thymidine at the indicated time after infection. The results are expressed as a relative
stimulation (stimulation index, SI)-i.e., increase over the [3H]thymidine incorporation in controls (cells treated with
empty RSVE). Repetitive experiments are listed from left to right in each column. [3H]Thymidine incorporation in controls
(empty RSVE) for the three experiments listed in column 1 (1 week) were (in cpm): 2301 ± 213, 707 ± 102, and 230 ± 121,
respectively. NT, not tested.
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phocytes was similar to that of Raji cells (not shown). The
amount of internalized DNA was usually lower, 4-5%.
Expression of the RSVE-Transferred EBV DNA and Cloned
DNA Fragments in Human B Lymphocytes. Transformation
of B cells by EBV involves stimulation of cellular DNA synthesis, induction of EBNA, cell division, and, finally, selfsustained outgrowth of EBV-infected B-cell lines (1, 3). We
followed all these parameters in B cells containing RSVEtransferred EBV DNA and fragments and compared them
with the cells infected with intact virus. The results are
shown in Table 2 and Figs. 3 and 4. EBV DNA induced a
significant increase in cellular DNA synthesis- 1.6-6.4
times the control (RSVE alone) levels. The extent of the
stimulation was lower than after exposure to intact EBV. As
shown in Fig. 3, stimulation was transient, decreasing to
control levels after 3 weeks in culture. RSVE-transferred
EBV DNA also induced ACIF-detectable EBNA in 0.2-1%
of the cells 48-72 hr after infection (Table 2). The proportion
of EBNA-positive cells decreased, and no cell transformation was observed.
Cloned regions of EBV DNA tested for the virus-related
functions included BamHI restriction endonuclease fragments D1, H, X, and K and Sal I F1 fragment. It has been
reported recently that the Sal I F1 fragment [9 kilobase pairs
(kbp)] or part of it obtained after digestion with BamHI endonuclease (BamHI K fragment, 5.2 kbp) contains gene(s)
coding for an EBNA-like antigen in mouse LTK- cells (10).

Proc. Natl. Acad. Sci. USA 81 (1984)
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Since EBNA has been postulated as a transforming antigen
of EBV (28, 29), we tested whether the EBV DNA region
containing EBNA-encoding gene(s) might act as an autonomous transforming unit. Neither Sal I F fragment nor
BamHI K fragment stimulated any significant cellular DNA
synthesis or caused cell transformation (Table 2 and Fig. 3).
The fragments induced EBNA in 2-4% of human lymphocytes. Fig. 4 A and B shows EBNA-expressing human B
cells detected by ACIF test 48 hr after Sal I F fragment
transfer, in comparison to the EBNA induction by intact virus (Fig. 4E).
We next tested fragments from the EBV DNA region that
is deleted in the nontransforming (but EBNA-inducing)
P3HR-1 virus (23, 25, 30). This region is encompassed within
the BamHI D1 fragment of the AG-876 EBV DNA or the
combined BamHI H-X fragments of B95-8 virus DNA (refs.
20-22; see also Fig. 1). The BamHI D1 or H-X fragments
transiently stimulated lymphocyte DNA synthesis. The stimulation was lower than after exposure to intact virion. In
contrast to EBV DNA, or Sal I F and BamHI K fragments,
BamHI D1 or H-X did not induce any ACIF-detectable
EBNA in human B cells. When both the Sal I F1 and BamHI
D1 fragments were introduced into the cells, the stimulation
of DNA synthesis by BamHI D1 alone was reduced, and no
cell transformation was achieved (Table 2). Plasmid DNA or
control empty RSVE did not have any effect on human lymphocyte DNA synthesis or EBNA expression.

FIG. 4. Expression of EBNA in lymphocytes after RSVE-mediated EBV DNA transfer: detection by immunofluorescence staining. Two
days after RSVE-mediated EBV DNA transfer, lymphocytes were fixed in acetone/methanol on glass slides and assayed by the ACIF technique as described (26). (A and B) Cells transferred with Sal I F1 fragment and stained with anti-EBNA-positive human serum (M.H.; antiEBNA titer 1:160, 1:10 dilution) as the first antibody. (C) Cells from the same system but stained with EBV-negative serum (C.K.; 1:10 dilution)
as the first antibody. (D) Cells transferred with BamHI DI fragment and stained with the anti-EBNA-positive M.H. serum. (E) Untreated cells
exposed to intact EBV and stained with the M.H. serum. (x500.)

5930
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Neither intact virus

nor

RSVE-transferred DNA or DNA

fragments induced EBV-determined antigens associated
with the lytic cycle of the virus, EA, and VCA (Table 2).

DISCUSSION
an efficient way of transferring
genetic information into fresh human lymphocytes. The procedure consists of two steps: (i) loading isolated SVE with
DNA and (ii) transferring DNA by following a spontaneous
fusion of hybrid RSVE/DNA vesicles with the target cells.
The natural process of envelope-cell fusion contributes to
the high transfer efficiency and limits cell damage. Since the
technique differs in principle from the other methods of gene
transfer, such as the DNA transfection or microinjection by
microcapillaries, we refer to it by the term RSVE-mediated
gene (DNA) transfer (13).
The RSVE-mediated gene transfer has been used in the
present work for studies on the expression of purified EBV
genome and cloned EBV DNA fragments in the natural target cells of the virus, the human B lymphocytes. We have
been interested in particular in evaluating the effect of DNA
fragments on cell proliferation and transformation and the
relationship of this phenomena to the induction of EBNA.
The following results are indicated. (i) Sal I F1 fragment and
BamHI K fragment of EBV DNA are capable of inducing
EBNA reactivity in normal human lymphocytes, confirming
the results previously obtained in tumor cells (10, 11). (ii)
The EBNA-inducing Sal I F1 and BamHI K fragments neither stimulated lymphocyte DNA synthesis nor transformed
the cells (Table 2), indicating that induction of EBNA reactivity by itself is not sufficient to achieve cell proliferation
and transformation. This finding is in contrast to previous
postulates suggesting that EBNA plays a direct role in stimulating and maintaining cell proliferation (28, 29). The discrepancy may be due to different experimental approaches. In
the experiments described by Klein et al. (28), purified
EBNA subcomponent (48 kDa) was microinjected into permanently growing mouse fibroblasts. Possibly, the fragment
further activated the existing growth-stimulatory mechanism
of the transformed cells. In our experiments, EBNA-encoding DNA fragments were introduced into resting normal lymphocytes. The observed lack of lymphocyte stimulation,
combined with the efficient expression of EBNA, makes it
unlikely that Sal I F1 or BamHI K fragments contain an autonomous lymphocyte-transforming gene. (iii) Transient cellular DNA synthesis-stimulatory activity was detected after
transfer of intact EBV DNA, the BamHI D1 region of AG876 virus DNA, and the combination of BamHI H and X
fragments of B95-8 DNA. It recently has been reported by
Glaser and colleagues that transfer of cloned BamHI X, H,
and F fragments (from B95-8 virus DNA) into a virus-nonproducer P3HR-1/epithelial hybrid tumor cell line resulted
in rescue of transforming virus (31), possibly as a result of
recombination between the fragments and the endogenous
P3HR-1 virus genome (32). As shown in our experiments,
these fragments alone are not sufficient for inducing B-cell
transformation. A mixture of BamHI D1 and Sal I F1 fragments was not capable of transforming the cells either, suggesting that still another region of the EBV DNA is necessary for stabilizing the DNA synthesis-stimulating and
EBNA-inducing activities of BamHI D1 (or BamHI H-X)
and Sal I F1 (BamHI K) fragments, respectively. This could
be, for example, the EcoRI joining (J) region coding for the
most abundant mRNA detected during lymphocyte transformation by an intact virus (33).
Our results suggest that transformation of human lymphocytes by EBV may require functional collaboration between
several viral and perhaps cellular genes. The approach described in this work may permit identification of these genes.
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